## International Neuromuscular COVID-19 Database

Resize font:

The International Neuromuscular COVID-19 Database is a paediatric and adult database to monitor and report on outcomes of "Coronavirus Disease 2019" (COVID-19) occurring in patients with Neuromuscular Diseases. There is an urgent need to understand outcomes of patients who acquire "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) infection and are receiving immunosuppressants and/or have disease features (e.g. cardiac or respiratory involvement) that may affect the outcome of COVID-19. This will help guide neuromuscular specialists and other health care professionals in advising and caring for their patients.

Please note, this survey is for health care professionals caring for paediatric or adult neuromuscular patients. Reporting a case to this registry should take 10-15 minutes. Please also report if you have a high suspicions of COVID-19 infection in your patients and indicate that this is unconfirmed. Patients' identifiers such as name or date of birth are NOT collected.

After submitting a case you will receive a link allowing you to return to the same case to update/complete data.

Please report after a minimum of 7 days and sufficient time has passed to observe the disease course through resolution of acute illness and/or death although we appreciate your time is pressured and precious currently. You may not have access to information to answer all questions. Do your best.

Please note that if you are reporting a case of Mitochondrial Disease or a case of Guillain-Barré Syndrome (GBS) associated with COVID-19 you will be asked to submit a second short disease specific-form that will pop-up after the first form is completed.

Please contact Smaragda Agathou (<u>s.agathou@ucl.ac.uk</u>) if you have any questions about the database. Please note that this email address is for technological clarifications about the database and NOT for patient data and queries.

F	amily name/last name of reporting provider
	f must provide value
(	Given name/first name of reporting provider
4	f must provide value
E	Email address
	f must provide value
ſ	
ı	nstitutional email preferred
F	Role of reporting provider (e.g., physician, nurse, etc.)
	Specialty of reporting provider
	· · · · · ·
ŀ	Hospital or clinic name
	must provide value
(	City of hospital/clinic
	r must provide value
+	
-	
	Country of hospital/clinic
(	Country of hospital/clinic  f must provide value

Local ID for case (optiona	ıl)	
Patient age * must provide value		
0-120 years		
Patient sex at birth  * must provide value		
	Female	
	Male	
	Other or not known	
Race/ethnic origin		
+ Arab		
Black		
+ East Asian		)
South Asian		
West Asian / Mic	idle Eastern	
Pacific Islander		
Latin American		
+ White		
Native American	n / Aboriginal / 1st Nations	
Unknown or pre	fer not to answer	
Check all that apply		
Smoking Status		
	Current smoker	
	Former smoker	
	Never smoked	
	Unknown smoking status	
	Unknown smoking status	

oes the patient currently use e-cigarettes or vape?	
Current smoker	
Former smoker	
Never smoked	
Unknown smoking status	
as the patient had the seasonal flu vaccination this season?	
Yes	
No	
Unknown	
£	
formation	
OVID-19 Diagnosis: How was the COVID-19 diagnosis made?  Presumptive diagnosis based on symptoms only	
	4
+ PCR swabs	_
+ Antibody/Serology	_
Metagenomic testing	
+ Chest radiograph (X-ray)	
+ CT scan	)
+ Laboratory assay, type unknown	)
€ CSF	7
+ Unknown	
<b>✓</b> Other	
Option available for new GBS cases only: Presented during pandemic but without COVID-19 specific symptoms or confirmatory tests (if choosing this option please use date of onset of GBS symptoms in date of COVID-19 diagnosis	
neck all that apply	
OVID-19 Diagnosis: other diagnostic testing, please specify:	
ate of COVID-19 diagnosis (or presumptive diagnosis): Day	
must provide value	
ate of COVID-19 diagnosis (or presumptive diagnosis): Month	
must provide value	~

ow did you become aware of this neuromuscular patient with COVID-19 (or presumptive  I am/was one of the patient's primary COVID-19 carers  This patient is under the care of my team/department and I became aware that the patient has/had COVID-19  1+2 above  I was consulted about this patient but I am/was not one of the patient's primary COVID-19 carers and the patient is not under the care of my team/department  Other  ther type of awareness of neuromuscular patient with COVID-19 (or presumptive COVID pecify:  Offection Acquisition: In the 14 days before onset of illness did the patient have any of the History of travel to an area with documented cases of COVID-19 infection  Close contact with a confirmed or probable case of COVID-19 infection  Presence in a healthcare facility where COVID-19 infections have been managed  Direct contact with an health care professional (in the community)	A did you become aware of this neuromuscular patient with COVID-19 (or presumptive I am/was one of the patient's primary COVID-19 carers  This patient is under the care of my team/department and I became aware that the patient has/had COVID-19  1+2 above  I was consulted about this patient but I am/was not one of the patient's primary COVID-19 carers and the patient is not under the care of my team/department  Other  Other  The type of awareness of neuromuscular patient with COVID-19 (or presumptive COVID-19) (or presumptive COVID-19).  City:  Close contact with a confirmed or probable case of COVID-19 infection  Close contact with a confirmed or probable case of COVID-19 infection  Presence in a healthcare facility where COVID-19 infections have been managed  Direct contact with an health care professional (in the community)  None of the above (community acquired - but no known direct contact with an health care professional)  Unknown  Other		2019
ow did you become aware of this neuromuscular patient with COVID-19 (or presumptive  I am/was one of the patient's primary COVID-19 carers  This patient is under the care of my team/department and I became aware that the patient has/had COVID-19  1 + 2 above  I was consulted about this patient but I am/was not one of the patient's primary COVID-19 carers and the patient is not under the care of my team/department  Other  Other  ther type of awareness of neuromuscular patient with COVID-19 (or presumptive COVID-pecify:  Infection Acquisition: In the 14 days before onset of illness did the patient have any of the History of travel to an area with documented cases of COVID-19 infection  Close contact with a confirmed or probable case of COVID-19 infection  Presence in a healthcare facility where COVID-19 infections have been managed  Direct contact with an health care professional (in the community)	I am/was one of the patient's primary COVID-19 (or presumptive I am/was one of the patient's primary COVID-19 carers  This patient is under the care of my team/department and I became aware that the patient has/had COVID-19  1+2 above  I was consulted about this patient but I am/was not one of the patient's primary COVID-19 carers and the patient is not under the care of my team/department  Other  Other  The type of awareness of neuromuscular patient with COVID-19 (or presumptive COVID-19 (o		2020
I am/was one of the patient's primary COVID-19 carers  This patient is under the care of my team/department and I became aware that the patient has/had COVID-19  1+2 above  I was consulted about this patient but I am/was not one of the patient's primary COVID-19 carers and the patient is not under the care of my team/department  Other  ther type of awareness of neuromuscular patient with COVID-19 (or presumptive COVID-pecify:  Infection Acquisition: In the 14 days before onset of illness did the patient have any of the History of travel to an area with documented cases of COVID-19 infection  History of travel to an area with documented case of COVID-19 infection  Presence in a healthcare facility where COVID-19 infections have been managed  Direct contact with an health care professional (in the community)	I am/was one of the patient's primary COVID-19 carers  This patient is under the care of my team/department and I became aware that the patient has/had COVID-19  1 + 2 above  I was consulted about this patient but I am/was not one of the patient's primary COVID-19 carers and the patient is not under the care of my team/department  Other  Other  Her type of awareness of neuromuscular patient with COVID-19 (or presumptive COVID-cify:  ection Acquisition: In the 14 days before onset of illness did the patient have any of the History of travel to an area with documented cases of COVID-19 infection  Close contact with a confirmed or probable case of COVID-19 infection  Presence in a healthcare facility where COVID-19 infections have been managed  Direct contact with an health care professional (in the community)  None of the above (community acquired - but no known direct contact with an health care professional)  Unknown  Other		2021
I am/was one of the patient's primary COVID-19 carers  This patient is under the care of my team/department and I became aware that the patient has/had COVID-19  1+2 above  I was consulted about this patient but I am/was not one of the patient's primary COVID-19 carers and the patient is not under the care of my team/department  Other  ther type of awareness of neuromuscular patient with COVID-19 (or presumptive COVID-pecify:  Infection Acquisition: In the 14 days before onset of illness did the patient have any of the History of travel to an area with documented cases of COVID-19 infection  History of travel to an area with documented case of COVID-19 infection  Presence in a healthcare facility where COVID-19 infections have been managed  Direct contact with an health care professional (in the community)	I am/was one of the patient's primary COVID-19 carers  This patient is under the care of my team/department and I became aware that the patient has/had COVID-19  1 + 2 above  I was consulted about this patient but I am/was not one of the patient's primary COVID-19 carers and the patient is not under the care of my team/department  Other  Other  Her type of awareness of neuromuscular patient with COVID-19 (or presumptive COVID-cify:  ection Acquisition: In the 14 days before onset of illness did the patient have any of the History of travel to an area with documented cases of COVID-19 infection  Close contact with a confirmed or probable case of COVID-19 infection  Presence in a healthcare facility where COVID-19 infections have been managed  Direct contact with an health care professional (in the community)  None of the above (community acquired - but no known direct contact with an health care professional)  Unknown  Other		
This patient is under the care of my team/department and I became aware that the patient has/had COVID-19  1 + 2 above  I was consulted about this patient but I am/was not one of the patient's primary COVID-19 carers and the patient is not under the care of my team/department  Other  Other  ther type of awareness of neuromuscular patient with COVID-19 (or presumptive COVID-pecify:  Infection Acquisition: In the 14 days before onset of illness did the patient have any of the History of travel to an area with documented cases of COVID-19 infection  Close contact with a confirmed or probable case of COVID-19 infection  Presence in a healthcare facility where COVID-19 infections have been managed  Direct contact with an health care professional (in the community)	This patient is under the care of my team/department and I became aware that the patient has/had COVID-19  1+2 above  I was consulted about this patient but I am/was not one of the patient's primary COVID-19 carers and the patient is not under the care of my team/department  Other  Other  Her type of awareness of neuromuscular patient with COVID-19 (or presumptive COVID-cify:  Covident and the patient with accompany to the patient have any of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the patient have any of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have any of the covident accordance of the patient have accordance of the patient	low did you be	ecome aware of this neuromuscular patient with COVID-19 (or presumptive
I was consulted about this patient but I am/was not one of the patient's primary COVID-19 carers and the patient is not under the care of my team/department  Other  Other	I was consulted about this patient but I am/was not one of the patient's primary COVID-19 carers and the patient is not under the care of my team/department  Other		I am/was one of the patient's primary COVID-19 carers
I was consulted about this patient but I am/was not one of the patient's primary COVID-19 carers and the patient is not under the care of my team/department  Other  Other	I was consulted about this patient but I am/was not one of the patient's primary COVID-19 carers and the patient is not under the care of my team/department  Other	This patien	
Other  Ot	Other		1 + 2 above
ther type of awareness of neuromuscular patient with COVID-19 (or presumptive COVID-pecify:  Infection Acquisition: In the 14 days before onset of illness did the patient have any of the History of travel to an area with documented cases of COVID-19 infection  Close contact with a confirmed or probable case of COVID-19 infection  Presence in a healthcare facility where COVID-19 infections have been managed  Direct contact with an health care professional (in the community)	ner type of awareness of neuromuscular patient with COVID-19 (or presumptive COVID-cify:  ection Acquisition: In the 14 days before onset of illness did the patient have any of the  History of travel to an area with documented cases of COVID-19 infection  Close contact with a confirmed or probable case of COVID-19 infection  Presence in a healthcare facility where COVID-19 infections have been managed  Direct contact with an health care professional (in the community)  None of the above (community acquired - but no known direct contact with an health care professional)  Unknown		
refection Acquisition: In the 14 days before onset of illness did the patient have any of the  History of travel to an area with documented cases of COVID-19 infection  Close contact with a confirmed or probable case of COVID-19 infection  Presence in a healthcare facility where COVID-19 infections have been managed  Direct contact with an health care professional (in the community)	ection Acquisition: In the 14 days before onset of illness did the patient have any of the  History of travel to an area with documented cases of COVID-19 infection  Close contact with a confirmed or probable case of COVID-19 infection  Presence in a healthcare facility where COVID-19 infections have been managed  Direct contact with an health care professional (in the community)  None of the above (community acquired - but no known direct contact with an health care professional)  Unknown		Other
refection Acquisition: In the 14 days before onset of illness did the patient have any of the  History of travel to an area with documented cases of COVID-19 infection  Close contact with a confirmed or probable case of COVID-19 infection  Presence in a healthcare facility where COVID-19 infections have been managed  Direct contact with an health care professional (in the community)	ection Acquisition: In the 14 days before onset of illness did the patient have any of the  History of travel to an area with documented cases of COVID-19 infection  Close contact with a confirmed or probable case of COVID-19 infection  Presence in a healthcare facility where COVID-19 infections have been managed  Direct contact with an health care professional (in the community)  None of the above (community acquired - but no known direct contact with an health care professional)  Unknown		
Direct contact with an health care professional (in the community)  None of the above (community acquired - but no known direct contact with an	Direct contact with an health care professional (in the community)     None of the above (community acquired - but no known direct contact with an health care professional)     Unknown		and the second s
None of the above (community acquired - but no known direct contact with an	None of the above (community acquired - but no known direct contact with an health care professional)  Unknown  Other	\	
	health care professional)  Unknown  Other	+ Close o	contact with a confirmed or probable case of COVID-19 infection
- Health care professional)	<b>⊘</b> Other	+ Close c	contact with a confirmed or probable case of COVID-19 infection  nce in a healthcare facility where COVID-19 infections have been managed
+ Unknown		+ Close c + Presen + Direct None c	contact with a confirmed or probable case of COVID-19 infection  nce in a healthcare facility where COVID-19 infections have been managed  contact with an health care professional (in the community)  of the above (community acquired - but no known direct contact with an
<b>✓</b> Other	ck all that apply	+ Close c + Presen + Direct + None c health	contact with a confirmed or probable case of COVID-19 infection  nce in a healthcare facility where COVID-19 infections have been managed  contact with an health care professional (in the community)  of the above (community acquired - but no known direct contact with an a care professional)
neck all that apply		+ Close c + Presen + Direct + None c health + Unkno	contact with a confirmed or probable case of COVID-19 infection  nce in a healthcare facility where COVID-19 infections have been managed  contact with an health care professional (in the community)  of the above (community acquired - but no known direct contact with an a care professional)
OVID-19 other infection acquisition, please specify:		+ Close of Present + Direct + None of health + Unkno  Other  meck all that apply	contact with a confirmed or probable case of COVID-19 infection  nce in a healthcare facility where COVID-19 infections have been managed  contact with an health care professional (in the community)  of the above (community acquired - but no known direct contact with an a care professional)  own
OVID-19 other infection acquisition, please specify:		+ Close c + Presen + Direct + None c health + Unkno Other heck all that apply	contact with a confirmed or probable case of COVID-19 infection  nce in a healthcare facility where COVID-19 infections have been managed  contact with an health care professional (in the community)  of the above (community acquired - but no known direct contact with an a care professional)  own
OVID-19 other infection acquisition, please specify:		+ Close c + Presen + Direct + None c health + Unkno Other	contact with a confirmed or probable case of COVID-19 infection  nce in a healthcare facility where COVID-19 infections have been managed  contact with an health care professional (in the community)  of the above (community acquired - but no known direct contact with an a care professional)  own
OVID-19 other infection acquisition, please specify:		+ Close c + Presen + Direct + None c health + Unkno Other heck all that apply	contact with a confirmed or probable case of COVID-19 infection  nce in a healthcare facility where COVID-19 infections have been managed  contact with an health care professional (in the community)  of the above (community acquired - but no known direct contact with an a care professional)  own
OVID-19 other infection acquisition, please specify:		+ Close of Present + Direct + None of health + Unkno  Other  meck all that apply	contact with a confirmed or probable case of COVID-19 infection  nce in a healthcare facility where COVID-19 infections have been managed  contact with an health care professional (in the community)  of the above (community acquired - but no known direct contact with an a care professional)  own

	Home or standalone testing (e.g. mobile testing site)	
	Nursing home or assisted living facility	
	Outpatient facility	
	Emergency department	
	Inpatient/hospital	
	Unknown	
	Other	
COVID-19 Diag	gnosis: other location, please specify:	
Has this patier	ent ever had symptoms of COVID-19 infection?	
	Yes	
	No	
	Unknown	

0	No treatment except supportive care
$\oplus$	Remdesivir
<b>•</b>	Lopinavir/ritonavir
lacktriangle	Oseltamivir
lacktriangle	Favipiravir
•	Darunavir
<b>(</b>	Azithromycin
lacktriangle	Anti-malarials (e.g. chloroquine, hydroxychloroquine)
•	IL-1b inhibitors (e.g., anakinra, canakinumab)
<b>(</b>	IL-6 inhibitors (e.g. tocilizumab, sarilumab, siltuximab)
<b>(</b>	Colchicine
•	Bevacizumab
	JAK inhibitors (e.g. tofacitinib, baricitinib, upadacitinib, ruxolitinib)
	Serpin inhibitors
	Ciclesonide
(B)	Glucocorticoids
(B)	IVIG
	Plasma from recovered patients
<b>(</b>	Antibiotics (either prophylactic or to treat secondary infection)
	Heparin (prophylactic doses)
<b>(</b>	Heparin (high doses)
<b>②</b>	Other
eck all	that apply
VID-	19: Treatment, additional notes/other:

Full recovery	
Resolved, with sequelae	
Deceased, due COVID-19	
Deceased, due to another reason (reason needs to be clearly not COVID-19 related)	
Vital status not known at this time	
Please confirm that the patient is dead  * must provide value	
Yes, the patient has died	
No, the patient has not died	
Approximate number of days from COVID-19 symptom onset to death:	
Outcome of COVID-19 is "Deceased, due to another reason (reason needs to be clearly needs)", please specify cause of death:	
related)", please specify cause of death:	
related)", please specify cause of death:  * must provide value	
related)", please specify cause of death:  * must provide value  Was the patient hospitalised during the illness?	
related)", please specify cause of death:  * must provide value  Was the patient hospitalised during the illness?  Yes	
related)", please specify cause of death:  * must provide value  Was the patient hospitalised during the illness?  Yes  No  Unknown	
related)", please specify cause of death:  * must provide value  Was the patient hospitalised during the illness?  Yes  No  Unknown  What was the maximum level of care required during the patient's illness (so far)?	
related)", please specify cause of death:  * must provide value  Was the patient hospitalised during the illness?  Yes  No  Unknown  What was the maximum level of care required during the patient's illness (so far)?  Did not require supplemental oxygen	
related)", please specify cause of death:  * must provide value  Was the patient hospitalised during the illness?  Yes  No  Unknown  What was the maximum level of care required during the patient's illness (so far)?  Did not require supplemental oxygen  Required supplemental oxygen	
related)", please specify cause of death:  * must provide value  Was the patient hospitalised during the illness?  Yes  No  Unknown  What was the maximum level of care required during the patient's illness (so far)?  Did not require supplemental oxygen  Required supplemental oxygen  Required non-invasive ventilation (NIV) or high flow oxygen devices	
related)", please specify cause of death:  * must provide value  Was the patient hospitalised during the illness?  Yes  No  Unknown  What was the maximum level of care required during the patient's illness (so far)?  Did not require supplemental oxygen  Required supplemental oxygen  Required non-invasive ventilation (NIV) or high flow oxygen devices  Required invasive mechanical ventilation	
related)", please specify cause of death:  * must provide value  Was the patient hospitalised during the illness?  Yes  No  Unknown  What was the maximum level of care required during the patient's illness (so far)?  Did not require supplemental oxygen  Required supplemental oxygen  Required non-invasive ventilation (NIV) or high flow oxygen devices  Required invasive mechanical ventilation  Required extracorporeal membrane oxygenation (ECMO)	
related)", please specify cause of death:  * must provide value  Was the patient hospitalised during the illness?  Yes  No  Unknown  What was the maximum level of care required during the patient's illness (so far)?  Did not require supplemental oxygen  Required supplemental oxygen  Required non-invasive ventilation (NIV) or high flow oxygen devices  Required invasive mechanical ventilation	

<ul> <li>♣ Acute Respiratory Distress Syndrome (ARDS)</li> <li>♣ Sepsis</li> <li>♣ Myocarditis or new heart failure</li> <li>♣ Concomitant or secondary infection (e.g. bacterial pneumonia, Influenza)</li> <li>♣ Cytokine storm or similar condition (e.g. macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis)</li> <li>♣ Venous tromboembolism (VTE) - deep vein thrombosis (DVT)</li> <li>♣ Venous tromboembolism (VTE) - pulmonary embolism (PE)</li> <li>♣ Acute kidney injury (AKI) / Acute kidney failure</li> <li>✔ Other serious complication</li> <li>**ckkall that apply</li> <li>**WID-19 complications: please specify other serious complications</li> </ul>	Sepsis      Myocarditis or new heart failure      Concomitant or secondary infection (e.g. bacterial pneumonia, Influenza)      Cytokine storm or similar condition (e.g. macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis)      Venous tromboembolism (VTE) - deep vein thrombosis (DVT)      Venous tromboembolism (VTE) - pulmonary embolism (PE)      Acute kidney injury (AKI) / Acute kidney failure  Other serious complication	•	No known complications
<ul> <li>Myocarditis or new heart failure</li> <li>Concomitant or secondary infection (e.g. bacterial pneumonia, Influenza)</li> <li>Cytokine storm or similar condition (e.g. macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis)</li> <li>Venous tromboembolism (VTE) - deep vein thrombosis (DVT)</li> <li>Venous tromboembolism (VTE) - pulmonary embolism (PE)</li> <li>Acute kidney injury (AKI) / Acute kidney failure</li> <li>Other serious complication</li> </ul>	<ul> <li>Myocarditis or new heart failure</li> <li>Concomitant or secondary infection (e.g. bacterial pneumonia, Influenza)</li> <li>Cytokine storm or similar condition (e.g. macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis)</li> <li>Venous tromboembolism (VTE) - deep vein thrombosis (DVT)</li> <li>Venous tromboembolism (VTE) - pulmonary embolism (PE)</li> <li>Acute kidney injury (AKI) / Acute kidney failure</li> <li>Other serious complication</li> </ul>	<b>(</b>	Acute Respiratory Distress Syndrome (ARDS)
Cytokine storm or similar condition (e.g. macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis)  Venous tromboembolism (VTE) - deep vein thrombosis (DVT)  Venous tromboembolism (VTE) - pulmonary embolism (PE)  Acute kidney injury (AKI) / Acute kidney failure  Other serious complication  ack all that apply	Cytokine storm or similar condition (e.g. macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis)  Venous tromboembolism (VTE) - deep vein thrombosis (DVT)  Venous tromboembolism (VTE) - pulmonary embolism (PE)  Acute kidney injury (AKI) / Acute kidney failure  Other serious complication  ck all that apply	•	Sepsis
Cytokine storm or similar condition (e.g. macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis)  Venous tromboembolism (VTE) - deep vein thrombosis (DVT)  Venous tromboembolism (VTE) - pulmonary embolism (PE)  Acute kidney injury (AKI) / Acute kidney failure  Other serious complication  ock all that apply	Cytokine storm or similar condition (e.g. macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis)      Venous tromboembolism (VTE) - deep vein thrombosis (DVT)      Venous tromboembolism (VTE) - pulmonary embolism (PE)      Acute kidney injury (AKI) / Acute kidney failure      Other serious complication  ck all that apply	( <del>-</del>	Myocarditis or new heart failure
syndrome/reactive hemophagocytic lymphohistiocytosis)  • Venous tromboembolism (VTE) - deep vein thrombosis (DVT)  • Venous tromboembolism (VTE) - pulmonary embolism (PE)  • Acute kidney injury (AKI) / Acute kidney failure  • Other serious complication  • eck all that apply	syndrome/reactive hemophagocytic lymphohisticytosis)  Venous tromboembolism (VTE) - deep vein thrombosis (DVT)  Venous tromboembolism (VTE) - pulmonary embolism (PE)  Acute kidney injury (AKI) / Acute kidney failure  Other serious complication  ck all that apply	<b>(</b>	Concomitant or secondary infection (e.g. bacterial pneumonia, Influenza)
Venous tromboembolism (VTE) - pulmonary embolism (PE)      Acute kidney injury (AKI) / Acute kidney failure  Other serious complication  ack all that apply	Venous tromboembolism (VTE) - pulmonary embolism (PE)     Acute kidney injury (AKI) / Acute kidney failure  Other serious complication  ck all that apply	•	Cytokine storm or similar condition (e.g. macrophage activation syndrome/reactive hemophagocytic lymphohistiocytosis)
Acute kidney injury (AKI) / Acute kidney failure  Other serious complication  ock all that apply	Acute kidney injury (AKI) / Acute kidney failure  Other serious complication  ck all that apply	<b>(</b>	Venous tromboembolism (VTE) - deep vein thrombosis (DVT)
Other serious complication  eck all that apply	Other serious complication  ck all that apply	<b>(</b>	Venous tromboembolism (VTE) - pulmonary embolism (PE)
eck all that apply	ck all that apply	<b>(</b>	Acute kidney injury (AKI) / Acute kidney failure
		<b>②</b>	Other serious complication
VID-19 complications: please specify other serious complications	VID-19 complications: please specify other serious complications	neck all t	that apply
		OVID-1	19 complications: please specify other serious complications

Acute disseminated encephalomyelitis (ADEM)  Acute flaccid paralysis  Aseptic meningitis  Ataxia  Cranial neuropathy  Encephalopathy-Encephalitis  Epilepsy-Epilepsia Partialis Continua  Gillain-Barré syndrome  Haemorragic stroke  Ischaemic stroke  Hyperkinetic movement disorder  Neuralgia  Vasculitis  Venous sinus thrombosis  Other serious neurological complication  check all that apply  COVID-19 complications: please specify other serious complications  Time frame (number of days) of neurological complication(s) post primary infection:		19: Neurological Complications	
Acute flaccid paralysis  Aseptic meningitis  Ataxia  Cranial neuropathy  Encephalopathy-Encephalitis  Fillepsy-Epilepsia Partialis Continua  Gillain-Barré syndrome  Haemorragic stroke  Ischaemic stroke  Hyperkinetic movement disorder  Neuralgia  Vasculitis  Venous sinus thrombosis  Other serious neurological complication  check all that apply  COVID-19 complications: please specify other serious complications	U	No known neurological complications	
Aseptic meningitis  Ataxia  Cranial neuropathy  Encephalopathy-Encephalitis  Fillepsy-Epilepsia Partialis Continua  Gillain-Barré syndrome  Haemorragic stroke  Ischaemic stroke  Hyperkinetic movement disorder  Neuralgia  Vasculitis  Venous sinus thrombosis  Other serious neurological complication  Check all that apply  COVID-19 complications: please specify other serious complications	•	Acute disseminated encephalomyelitis (ADEM)	
Ataxia  Cranial neuropathy  Encephalopathy-Encephalitis  Gillain-Barré syndrome  Haemorragic stroke  Ischaemic stroke  Hyperkinetic movement disorder  Neuralgia  Vasculitis  Venous sinus thrombosis  Other serious neurological complication  check all that apply  COVID-19 complications: please specify other serious complications	<b>(</b>	Acute flaccid paralysis	
<ul> <li>Cranial neuropathy</li> <li>Encephalopathy-Encephalitis</li> <li>Epilepsy-Epilepsia Partialis Continua</li> <li>Gillain-Barré syndrome</li> <li>Haemorragic stroke</li> <li>Ischaemic stroke</li> <li>Hyperkinetic movement disorder</li> <li>Neuralgia</li> <li>Vasculitis</li> <li>Venous sinus thrombosis</li> <li>Other serious neurological complication</li> <li>check all that apply</li> </ul> COVID-19 complications: please specify other serious complications	•	Aseptic meningitis	
<ul> <li>♣ Encephalopathy-Encephalitis</li> <li>♣ Epilepsy-Epilepsia Partialis Continua</li> <li>♣ Gillain-Barré syndrome</li> <li>♣ Haemorragic stroke</li> <li>♣ Ischaemic stroke</li> <li>♣ Hyperkinetic movement disorder</li> <li>♠ Neuralgia</li> <li>♣ Vasculitis</li> <li>♣ Venous sinus thrombosis</li> <li>✔ Other serious neurological complication check all that apply</li> </ul> COVID-19 complications: please specify other serious complications	<b>(</b>	Ataxia	
<ul> <li>⊕ Epilepsy-Epilepsia Partialis Continua</li> <li>⊕ Gillain-Barré syndrome</li> <li>⊕ Haemorragic stroke</li> <li>⊕ Ischaemic stroke</li> <li>⊕ Hyperkinetic movement disorder</li> <li>⊕ Neuralgia</li> <li>⊕ Vasculitis</li> <li>⊕ Venous sinus thrombosis</li> <li>✓ Other serious neurological complication</li> <li>check all that apply</li> </ul> COVID-19 complications: please specify other serious complications	<b>(</b>	Cranial neuropathy	
<ul> <li>⊕ Gillain-Barré syndrome</li> <li>⊕ Haemorragic stroke</li> <li>⊕ Ischaemic stroke</li> <li>⊕ Hyperkinetic movement disorder</li> <li>⊕ Neuralgia</li> <li>⊕ Vasculitis</li> <li>⊕ Venous sinus thrombosis</li> <li>✓ Other serious neurological complication</li> <li>check all that apply</li> </ul> COVID-19 complications: please specify other serious complications	<b>(</b>	Encephalopathy-Encephalitis	
<ul> <li>⊕ Haemorragic stroke</li> <li>⊕ Ischaemic stroke</li> <li>⊕ Hyperkinetic movement disorder</li> <li>⊕ Neuralgia</li> <li>⊕ Vasculitis</li> <li>⊕ Venous sinus thrombosis</li> <li>✓ Other serious neurological complication</li> <li>check all that apply</li> </ul> COVID-19 complications: please specify other serious complications	•	Epilepsy-Epilepsia Partialis Continua	
<ul> <li>↓ Ischaemic stroke</li> <li>⊕ Hyperkinetic movement disorder</li> <li>⊕ Neuralgia</li> <li>⊕ Vasculitis</li> <li>⊕ Venous sinus thrombosis</li> <li>✓ Other serious neurological complication</li> <li>check all that apply</li> </ul> COVID-19 complications: please specify other serious complications	<b>(</b>	Gillain-Barré syndrome	
<ul> <li>→ Hyperkinetic movement disorder</li> <li>→ Neuralgia</li> <li>→ Vasculitis</li> <li>→ Venous sinus thrombosis</li> <li>✓ Other serious neurological complication</li> <li>check all that apply</li> </ul> COVID-19 complications: please specify other serious complications	<b>(</b>	Haemorragic stroke	
<ul> <li>→ Neuralgia</li> <li>→ Vasculitis</li> <li>→ Venous sinus thrombosis</li> <li>✓ Other serious neurological complication</li> <li>check all that apply</li> </ul> COVID-19 complications: please specify other serious complications	0	Ischaemic stroke	
<ul> <li>→ Vasculitis</li> <li>→ Venous sinus thrombosis</li> <li>✓ Other serious neurological complication</li> <li>check all that apply</li> <li>COVID-19 complications: please specify other serious complications</li> </ul>	<b>(</b>	Hyperkinetic movement disorder	
Other serious neurological complication  check all that apply  COVID-19 complications: please specify other serious complications	•	Neuralgia	
Other serious neurological complication  check all that apply  COVID-19 complications: please specify other serious complications	<b>(</b>	Vasculitis	
check all that apply  COVID-19 complications: please specify other serious complications	<b>(</b>	Venous sinus thrombosis	
COVID-19 complications: please specify other serious complications	<b>②</b>	Other serious neurological complication	
	check all	that apply	
Time frame (number of days) of neurological complication(s) post primary infection:	COVID-	19 complications: please specify other serious complications	
Time frame (number of days) of neurological complication(s) post primary infection:			
	Time fr	ame (number of days) of neurological complication(s) post primary infection:	
	ıscular d		
Neuromuscular diagnosis  * must provide value	Neuron		
Neuromuscular diagnosis  * must provide value  Motor neurone disease	Neuron	rovide value	
* must provide value	Neuron	Motor neurone disease	
* must provide value  Motor neurone disease  Dermatomyositis	Neuron	Motor neurone disease  Dermatomyositis	
* must provide value  Motor neurone disease  Dermatomyositis  Anti-synthetase syndrome	Neuron	Motor neurone disease  Dermatomyositis  Anti-synthetase syndrome	
* must provide value  Motor neurone disease  Dermatomyositis  Anti-synthetase syndrome  Immune mediated necrotising myopathy	Neuron	Motor neurone disease  Dermatomyositis  Anti-synthetase syndrome  Immune mediated necrotising myopathy	
* must provide value  Motor neurone disease  Dermatomyositis  Anti-synthetase syndrome  Immune mediated necrotising myopathy  Inclusion Body Myositis (IBM)	Neuron	Motor neurone disease  Dermatomyositis  Anti-synthetase syndrome  Immune mediated necrotising myopathy  Inclusion Body Myositis (IBM)	
* must provide value  Motor neurone disease  Dermatomyositis  Anti-synthetase syndrome  Immune mediated necrotising myopathy	Neuron	Motor neurone disease  Dermatomyositis  Anti-synthetase syndrome  Immune mediated necrotising myopathy  Inclusion Body Myositis (IBM)  Other idiopathic inflammatory myopathy	

	Facioscapulohumeral muscular dystrophy (FSHD)
	Other limb girdle muscular dystrophy (LGMD)
	Myotonic dystrophy
	Myofibrillar myopathy
	Congenital muscular dystrophy
	Spinal Muscular Atrophy
	Congenital myopathy
	Fatty acid oxidation disorder
	Pompe disease (GSD type II)
	Other glycogen storage diseases
	Skeletal muscle channelopathy
	Mitochondrial disease
	Guillain-Barré syndrome
	Vasculitis (any)
	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
	POEMS syndrome
	Paraproteinaemic neuropathy
	Multifocal motor neuropathy
	ldiopathic neuropathy
	Inherited neuropathy
	Amyloid neuropathy
	Autonomic neuropathy
ı	Myasthenia Gravis (AChR and MuSK antibody positive and negative)
	Lambert Eaton myasthenic syndrome
	Fast channel congenital myasthenic syndrome
	Congenital myasthenic syndrome
	Ocular myasthenia
	Undetermined genetic neuromuscular or neurological disorder
	Other

	pre-existing or new (triggered by SARS-CoV-2) neuromuscular diagnosis?  ovide value
	Pre-existing neuromuscular diagnosis
	New neuromuscular diagnosis (triggered by SARS-CoV-2)
	Unknown
	ny of the following neuromuscular disease-related features present at the time of Commonset (or at COVID-19 diagnosis if asymptomatic)?
<b>(</b>	Ventilated - tracheostomy
<b>(</b>	Non invasive ventilation (BiPAP, CPAP)
<b>(</b>	Forced Vital Capacity (FVC) less than 60%
<b>(</b>	Dysphagia
$\odot$	Enteral nutrition (e.g. PEG, RIG)
<b>(</b>	Cardiac involvement of neuromuscular disease (e.g. cardiomyopathy)
•	Severely impaired cardiac function (LVEF < 30%)
( <b>a</b>	Pacemaker
<b>(</b>	ICD
<b>(</b>	Able to walk with aids or part-time wheelchair user
<b>(</b>	Full-time wheelchair user
<b>(</b>	None present
<b>(</b>	Unknown
34	that apply

## Modified Rankin Scale BEFORE onset of COVID-19 No symptoms No significant disability. Able to carry out all usual activities, despite some symptoms Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities Moderate disability. Requires some help, but able to walk unassisted Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted Severe disability. Requires constant nursing care and attention, bedridden, incontinent Unknown reset Modified Rankin Scale AFTER COVID-19 (last functional status known post-infection) No symptoms No significant disability. Able to carry out all usual activities, despite some symptoms Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities Moderate disability. Requires some help, but able to walk unassisted Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted Severe disability. Requires constant nursing care and attention, bedridden, incontinent Unknown Not applicable (outcome was death) reset Neuromuscular disease activity/control (if applicable to the disease) at the time of COVID-19 symptom onset (or at COVID-19 diagnosis if asymptomatic) Inactive diseases / remission / controlled Active disease / not controlled Not applicable Unknown reset Treatments for underlying neuromuscular disease

	Yes	
	No	
	Unknown	
	then dose ( <u>prednisone equivalent</u> ) at the time of COVID-19 sy	mpto
(or at COVID-19 diagnosis if	f asymptomatic):	
mg/day (enter number only)		
Was the glucocorticoid sto	opped or continued after COVID-19 diagnosis?	
	Stopped	
	Continued at same dose	
	Tapered dose	
	-	
	Increased dose	
	Undergone	
Immune modulating medicovID-19 diagnosis if asym	Unknown  ications immediately prior to the time of COVID-19 symptom  ptomatic)	onset
COVID-19 diagnosis if asym	ications immediately prior to the time of COVID-19 symptom	onset
COVID-19 diagnosis if asym	ications immediately prior to the time of COVID-19 symptom ptomatic)	onset
COVID-19 diagnosis if asym	ications immediately prior to the time of COVID-19 symptom ptomatic)  ampath)	onset
COVID-19 diagnosis if asymptons of the None	ications immediately prior to the time of COVID-19 symptom ptomatic)  ampath)  fenidone, nintedinib)	onset
COVID-19 diagnosis if asymptons of the None  + Abatacept  + Alemtuzumab (Call the Antifibrotics (pirture))  + Antimalarials (incompare)	ications immediately prior to the time of COVID-19 symptom ptomatic)  ampath)	onset
COVID-19 diagnosis if asymptons of the None	ications immediately prior to the time of COVID-19 symptom ptomatic)  ampath)  fenidone, nintedinib)	onset
COVID-19 diagnosis if asymptons of the None  + Abatacept  + Alemtuzumab (Call the Antifibrotics (pirture))  + Antimalarials (incompare)	ications immediately prior to the time of COVID-19 symptom ptomatic)  ampath)  fenidone, nintedinib)	onset
COVID-19 diagnosis if asymptotics (pires)  Abatacept  Alemtuzumab (Case)  Antifibrotics (pires)  Antimalarials (incompare)  Apheresis  Apremilast	ications immediately prior to the time of COVID-19 symptom ptomatic)  ampath)  fenidone, nintedinib)	onset
COVID-19 diagnosis if asymptotics (pires)  Abatacept  Alemtuzumab (Case)  Antifibrotics (pires)  Antimalarials (incompare)  Apheresis  Apremilast	ications immediately prior to the time of COVID-19 symptom ptomatic)  ampath)  fenidone, nintedinib)  cluding hydroxychloroquine, chloroquine)	onset
COVID-19 diagnosis if asymptotics (pires)  Abatacept  Alemtuzumab (Case)  Antifibrotics (pires)  Antimalarials (incompare)  Apheresis  Apremilast  Azathioprine / 6-1	ications immediately prior to the time of COVID-19 symptom ptomatic)  ampath)  fenidone, nintedinib)  cluding hydroxychloroquine, chloroquine)	onset
COVID-19 diagnosis if asymptotics (pires)  Abatacept  Alemtuzumab (Case)  Antifibrotics (pires)  Antimalarials (incompare)  Apheresis  Apremilast  Azathioprine / 6-1	ications immediately prior to the time of COVID-19 symptom ptomatic)  ampath)  fenidone, nintedinib)  cluding hydroxychloroquine, chloroquine)  mercaptopurine (6-MP)  (including rituximab within last 12 months, ofatumumab)	onset
COVID-19 diagnosis if asymptons of the None  Abatacept  Alemtuzumab (Call of the Antifibrotics (pirform)  Antimalarials (incomplete Apheresis  Apremilast  Azathioprine / 6-1  Belimumab  CD-20 inhibitors (	ications immediately prior to the time of COVID-19 symptom ptomatic)  ampath)  fenidone, nintedinib)  cluding hydroxychloroquine, chloroquine)  mercaptopurine (6-MP)  (including rituximab within last 12 months, ofatumumab)	onset
COVID-19 diagnosis if asymptotics (pires)  Abatacept  Alemtuzumab (Caster Antifibrotics (pires)  Antifibrotics (pires)  Antimalarials (incomplete Apheresis  Apheresis  Apremilast  Azathioprine / 6-1  Belimumab  CD-20 inhibitors (caster Appendix A	ications immediately prior to the time of COVID-19 symptom ptomatic)  ampath)  fenidone, nintedinib)  cluding hydroxychloroquine, chloroquine)  mercaptopurine (6-MP)  (including rituximab within last 12 months, ofatumumab)	onset

IL-6 inhibitors (including to	ocilizumab, sarilu	ımab)			
L-12/23 inhibitors (ustekin	( IL-12/23 inhibitors (ustekinumab)				
IL-23 inhibitors (guselkuma	IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab)				
IL-17 inhibitors (including s	IL-17 inhibitors (including secukinumab, ixekizumab)				
Intravenous immunoglobu	Intravenous immunoglobulin (IVIG)				
JAK inhibitors (including to	+ JAK inhibitors (including tofacitinib, baricitinib, upadacitinib)				
<b>Leflunomide</b>	+ Leflunomide				
(+) Methotrexate					
Mycophenolate mofetil / mycophenolic acid (Myfortic)					
+ Sulfasalazine					
<b>+</b> Tacrolimus					
Thalidomide / lenalidomide	e				
TNF-inhibitors (including adalimumab, certolizumab, etanercept, golimumab, infliximab, and biosimilars)					
+ Unknown				)	
+ Other					
Was Intravenous immunoglobulin (IV.	(G) stopped or co	ntinued after COVI	D-19 diagnosis?		
	Stopped				
	Continued				
Continued at lower dose or longer application interval					
Unknown					
					reset
At the time of COVID-19 symptom onset (or diffullowing medications?	iagnosis if asymp	tomatic), was the p	oatient taking any	of the	
	Yes and medication continued	Yes and medication stopped	No	Unknov	vn
ACE inhibitor	0	0	0	0	
Angiotensin receptor blocker	0	0	0	0	reset
Non-selective NSAIDs	0	0	0	0	reset
Selective NSAIDs (COX-2 inhibitors)	0	0	0	0	reset
PD5 inhibitor (e.g. sildenafil)	0	0	0	0	reset
Comorbidity and Pregnancy					
+ None					

Interstitial lung disease (e.g. NSIP, UIP, IPF) **Obstructive lung disease (COPD/asthma) Obstructive Sleep Apnoea (OSA) Restrictive lung disease** Other lung disease **Diabetes** Obesity (BMI >=30) Morbid obesity (BMI >=40) Hypertension Cardiovascular disease (coronary artery disease, congestive heart failure, arrhythmia) Cerebrovascular disease **Pulmonary hypertension** Chronic renal insufficiency or end stage renal disease Cancer **Organ transplant recipient Primary immunodeficiency** HIV Inflammatory bowel disease Liver disease Other chronic neurological disease (non-neuromuscular) Trisomy 21 Psychiatric condition (e.g., schizophrenia, bipolar disorder) **Rheumatological disease** Macrophage activation syndrome (prior to COVID-19 diagnosis) Atopic eczema **Congenital heart disease Psoriasis Pregnancy** Post-partum (< 6 weeks) Unknown

	<b>⊘</b> Other				
	Check all that apply				
	Other comorbidity - please specify:				
Laborator	Laboratory Test results (optional)				
	Are there any laboratory test results available related to this patient's COVID-19 infection? (optional)				
	Yes				
	No				
	Unknown				
		reset			
Follow-up	/Notes				
	May we contact you to get more information about the outcomes of this case?				
	Yes				
	No				
		reset			
,	Would you like to share any lessons or other aspects from this case?				
Please do not write any patient identifiable information in this box.					
		Expand			
	Do you have any comments or feedback on the survey itself?				
		Expand			
Information on how your personal data are processed is within this privacy notice:					
Attachment: Meuromuscular COVID-19 Database Privacy Notice.pdf (0.64 MB)					
	Submit				
Save & Return Later					
	Save & Return Later				

Powered by REDCap